#9 - Needs and Involvement of HIV Specialists and Geriatricians in the Care of Older Adults with HIV. A National Survey - Fátima Brañas

International Workshop on HIV & Aging 2022

#8 - Aging and HIV: What Is the Gap Between Clinical Practice and Guideline Recommendations? - Giovanni Guaraldi

International Workshop on HIV & Aging 2022

#7 - The Impending African Challenge: Gaps in 95-95-95 Performance Herald an Emerging Double-Disease Burden of Ageing and HIV (...) - Candice Fick

International Workshop on HIV & Aging 2022

Kidney Disease in Aging PLWHIV (Clinical Case Based) - Christina Wyatt, MD

International Workshop on HIV & Aging 2022

#6 - Social and Co-morbid Determinants of Brain Aging in Persons With and Without HIV - Kalen Petersen

International Workshop on HIV & Aging 2022

#5 - Individual and Community Measures of Depression and Risk of Non-communicable Disease Among Adults With HIV - Jessica Castilho

International Workshop on HIV & Aging 2022

#4 - Increasing Neuroinflammation Relates to Increasing Neurodegeneration in PWH - Azin Tavasoli

International Workshop on HIV & Aging 2022

Overlap Between Cognitive and Physical Frailty - Mary Clare Masters, MD

International Workshop on HIV & Aging 2022

Overlap Between HAND and Alzheimer Disease - Eliezer Masliah, MD

International Workshop on HIV & Aging 2022

#3 - Tenofovir Alafenamide Is Associated With Shorter Telomere Length in People With HIV - Upal Roy

International Workshop on HIV & Aging 2022

#2 - Persistent CD38 Expression on CD8+ T Lymphocytes Contributes to Chronic Inflammation in People With HIV, Despite ART - Poonam Mathur

International Workshop on HIV & Aging 2022

#1 - Early Interruptions in Treatment Among PLHIV Over 50 Years of Age Starting Antiretroviral Therapy in PEPFAR-Supported Low and Middle-Income Countries - Deidra Parrish

International Workshop on HIV & Aging 2022

Use of Senolytics as Modifiers of Aging Trajectory - James Kirkland, MD, PhD

International Workshop on HIV & Aging 2022

How Are We Measuring Aging/Which Different Methods Are Used to Assess Aging? - Luigi Ferrucci, MD, PhD

International Workshop on HIV & Aging 2022

Weighty Matters in HIV Treatment 2021 - Incorporating ARV Weight Gain into Clinical Decisions - François Venter

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - Clinical Case Presentation 2 - Focus on Women - Grace McComsey

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - Clinical Case Presentation 1 - Focus on Young MSM - Jürgen Rockstroh

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - What are the Clinical Consequences of ARV Induced Weight Gain and Other Metabolic Toxicities? - John Robert Koethe

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - ARV Associated Weight Gain: What are the Possible Mechanisms? - Laura Waters

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - ARV Associated Weight Gain: What are the Clinical Data? - Chloe Orkin

Weighty Matters in HIV Treatment 2021

Implementing Monoclonal Antibodies for Treatment and Prevention in Resource-Limited Settings - How to Make Them Affordable - Dr. Ripin

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

How Will Technology Evolve: Delivery Methods and Formulations - Dr. Appel

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

How Will Technology Evolve: Modification of Antibodies - Dr. Juelg

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibody Dosing in Pediatrics: Rational Basis and Examples - Dr. Meibohm

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021